SPAG9 promotes endometrial carcinoma cell invasion through regulation of genes related to the epithelial-mesenchymal transition

Objective: To investigate the impact of sperm-associated antigen 9 (SPAG9) on proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in endometrial cancer. Materials and Methods: The present authors' previous study demonstrated that SPAG9 is highly expressed in endometrial cancer tissues. They analyzed correlation between the levels of SPAG9 and mRNA of EMT-related genes in endometrial carcinoma tissue by using quantitative real-time PCR. They induced EMT process in ECC endometrial cancer cell lines by TGF-beta1 treatment and spheroids formation assay, and analyzed SPAG9 expression as well as correlation with EMT-related genes.In addition, they performed SPAG9 gene silencing in KLE and ECC endometrial cancer cells and evaluated the expression of genes involved in EMT, using real time PCR and Western blot analysis. Cell proliferation, colony formation, and transwell assays were employed to evaluate the functional role of SPAG9 in endometrial cancer. Results: The results showed that SPAG9 expression was positively correlated with Slug and N-cadherin (NcaD) in human endometrial cancer tissues. The expression of SPAG9 in ECC cells with TGF-β1 treatment and spheroids formation was increased, which was correlated with EMT-related genes. SPAG9 knockdown significantly inhibited cell growth and proliferation and reduced the motility and invasion of endometrial cancer cells. These phenotypes may partly be explained by decreased expression of EMT-related genes, including Twist, Slug, and Vimentin, after SPAG9 depletion. Conclusions: SPAG9 may be required for cellular invasion and migration in endometrial cancer through regulation of EMT-related genes.

Sperm-associated antigen 9 (SPAG9); Endometrial carcinoma; Epithelial–mesenchymal transition.

[1] “Netherlands Cancer Registry: 2001-2011”, based on April 2011 NCR data submission, posted to the NCR web site, 2011. Available at: http://www.cijfersoverkanker.nl/selecties/dataset_1/img56c32cc90a2bc?row=0&direction=down#table

[2] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11-30.

[3] Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., et al.: “Characterization of a novel human spermassociated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinaseinteracting protein”. Biochem., 2005, 389, 73.

[4] Garg M., Kanojia D., Khosla A., Dudha N., Sati S., Chaurasiya D., et al.: “Sperm associated antigen 9 is associated with tumor growth, migration and inv asion in renal cell carcinoma”. Cancer Res., 2008, 68, 8240.

[5] Kanojia D., Garg M., Gupta S., Gupta A., Suri A.: “Sperm associated antigen 9 (SPAG9), a novel biomarker for early detection of breast cancer”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 630.

[6] Kanojia D., Garg M., Gupta S., Gupta A., Suri A.: “Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity”. Am. J. Pathol., 2011, 178, 1009.

[7] Yi F., Ni W., Liu W., Pan X., Han X., Yang L., et al.: “SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion”. Tumour Biol., 2013, 34, 2849.

[8] Wang Y., Dong Q., Miao Y., Fu L., Lin X., Wang E.: “Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer”. Lung Cancer, 2013, 81, 266.

[9] Suri A., Saini S., Sinha A., Agarwal S., Verma A., Parashar D., et al.: Cancer testis antigens: a new paradigm for cancer therapy”. Oncoimmunology, 2012, 1, 1194.

[10] Van Slambrouck S., Grijelmo C., De Wever O., Bruyneel E., Emami S., Gespach C., et al.: “Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion”. Int. J. Oncol., 2007, 31, 1501.

[11] Chen H.H., Zhou X.L., Shi Y.L.,Yang J.: “Roles of p38 MAPK and in TGF-β1-induced human alveolar epithelial to mesenchymal transition”. Arch. Med. Res., 2013, 44, 93.

[12] Kang Y., Massagué J.: “Epithelial–mesenchymal transitions:Twist in development and metastasis”. Cell, 2004, 118, 277.

[13] Thiery J.P.: “Epithelial-mesenchymal transitions in tumour progression”. Nat. Rev. Cancer, 2002, 2, 442.

[14] Yin G., Alvero A.B., Craveiro V., Holmberg J.C., Fu H.H., Montagna M.K., et al.: “Constitutive proteasomal degradation of TWIST- 1 in epithelial--ovarian cancer stem cells impacts differentiation and metastatic potential”. Oncogene, 2012, 32, 39.

[15] Noh H., Oh E.Y., Seo J.Y., Yu M.R., Kim Y.O., Ha H., Lee H.B.: “Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-1 induced renal injury”. Am. J. Physiol. Renal Physiol., 2009, 297, F729.

[16] Yu P., Yan L., Zhang H., Lin X., Zhao X.: “Expression and clinical significance of sperm-associated antigen 9 in patients with endometrial carcinoma”. Int. J. Gynecol. Cancer, 2012, 22, 87.

[17] Zhang H., Li M., Zheng X.,Wen Z., Zhao X.: “Endometriotic stromal cells lose the ability to regulate cell-survival signaling in endometrial epithelial cells in vitro”. Mol. Hum. Reprod., 2009, 15, 653.

[18] Colas E., Pedrola N., Devis L., Ertekin T., Campoy I., Martínez E., et al.: “The EMT signaling pathways in endometrial carcinoma”. Clin. Transl. Oncol., 2012, 14, 715.

[19] Kyo S., Sakaguchi J., Ohno S., Mizumoto Y., Maida Y., Hashimoto M., et al.: “High Twist expression is involved in infiltrative endometrial cancer and affects patient survival”. Hum. Pathol., 2006, 37, 431.

[20] Yamada S., Fuchs B.C., Fujii T., Shimoyama Y., Sugimoto H., Nomoto S., et al.: “Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer”. Surgery, 2013, 154, 946.

[21] Toiyama Y., Yasuda H., Saigusa S., Tanaka K., Inoue Y., Goel A., Kusunoki M.: “Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poorprognosis in colorectal cancer”. Carcinogenesis, 2013, 34, 2548.

[22] Whiteland H., Spencer-Harty S., Thomas D.H., Davies C., Morgan C., Kynaston H., et al.: “Putative prognostic epithelial-tomesenchymal transition biomarkers for aggressive prostate cancer”. Exp. Mol. Pathol., 2013, 95, 220.